Not available
Quote | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)
Last: | $49.61 |
---|---|
Change Percent: | -1.98% |
Open: | $50.76 |
Close: | $50.61 |
High: | $51.25 |
Low: | $49.34 |
Volume: | 485,084 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
News | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Message Board Posts | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $IONS News Article - Biogen and Alcyone Therapeutics Announce License and Collaboration | whytestocks | investorshangout | 01/04/2023 9:00:53 PM |
whytestocks: $IONS News Article - Ionis announces eplontersen met co-primary and secondary endpoints | whytestocks | investorshangout | 06/21/2022 5:35:59 PM |
whytestocks: $IONS News Article - Ionis partner Biogen announces that results from Phase 3 VALOR stu | whytestocks | investorshangout | 06/03/2022 5:05:51 PM |
whytestocks: $IONS News Article - Ionis to hold first quarter 2022 financial results webcast | whytestocks | investorshangout | 04/20/2022 6:05:51 PM |
whytestocks: $IONS News Article - Ionis announces positive data for ETESIAN Phase 2b study of antise | whytestocks | investorshangout | 04/04/2022 12:25:53 PM |
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...